OHSU Announces Marquam Hill Lecture Series for 2010-11

WHAT: 

The Oregon Health & Science University's Marquam Hill Lecture Series features nationally recognized OHSU faculty experts who present in lay terms the latest research findings and treatment options in their specialties. All lectures are free, but seating is limited and reservations are requested. For more information, call 503 418-9793 or send an e-mail to kollenbu@ohsu.edu.

WHEN/WHERE:

Thursdays, 7:30 p.m., OHSU Auditorium (Old Library building)
3181 S.W. Sam Jackson Park Road, Portland, OR 97239

* Note: The Monday, March 21, 2011, Substance Abuse lecture presented by Robert Hitzemann, Ph.D., begins at 7 p.m. and will be held at the Newmark Theatre, 1111 S.W. Broadway, Portland, OR 97205. Tickets, available at no charge, are required to attend this lecture. Please reserve space at this lecture only by calling the Portland Center for the Performing Arts at 503 432-2917. This lecture is presented in conjunction with the OHSU Brain Awareness lecture series.

DETAILS:

Thursday, Oct. 21, 2010 — "The Future of Interventional Cardiology: Or Are We There Already?" Saurabh Gupta, M.D., assistant professor of medicine (cardiovascular medicine), OHSU School of Medicine

Using research data and a series of animations, Gupta will guide attendees through the body's vascular system into the heart to demonstrate new and innovative uses for stents, balloons and umbrellas in catheter-based treatments for structural heart defects.

Thursday, Nov. 18, 2010 — "Rare Disorders: Challenges for Physicians and Familes," Susan Hayflick, M.D., professor and interim chair of molecular and medical genetics, OHSU School of Medicine.

Rare diseases are those that affect fewer than 200,000 Americans at any given time. Nearly 7,000 such diseases are known today, many of them targeting children and all impacting patients and families. Hayflick has dedicated her research to finding a cure for neurodegeneration with brain iron accumulation (NBIA), a group of rare, genetic neurological disorders. Hayflick will discuss the science that many of these rare diseases share and the social and economic challenges that these patients face.

• Thursday, Feb. 17, 2011— "Gene and Stem Cell Therapy for Eye Disease," Peter Francis, M.D., Ph.D., associate professor of ophthalmology, OHSU School of Medicine; and director, Translational Clinical Trials Center, OHSU Casey Eye Institute

Retinal degeneration, often inherited, is largely untreatable and affects millions of people in the United States. Ophthalmic geneticists are investigating the use of stem cells and gene therapy for retinal diseases. Francis will discuss his research into care of the retina, age-related macular degeneration and congenital eye diseases.

• *Monday, March 21, 2011 — "Forty Years in Alcohol and Drug Abuse Research: A Personal History," Robert Hitzemann, Ph.D., professor and chair of behavioral neuroscience, OHSU School of Medicine

Part science, part history, Hitzemann's story of 40 years of research into substance abuse begins when researchers knew of the existence of only four neurotransmitters, and considered hallucinogens to be an appropriate model for schizophrenia research. Researchers now study many hundreds of neurotransmitters, employ sophisticated techniques to help us better understand the chemistry of substance abuse in the brain, and guide clinical and societal solutions to its impacts.

• Thursday, April 21, 2011 — "Neuroprotection and Stroke: New Strategies to Protect Against Brain Injury," Mary Stenzel-Poore, Ph.D., professor and chair of molecular microbiology and immunology and associate dean for basic science, OHSU School of Medicine

Current clinical treatments for stroke focus on rapidly applied, post-stroke therapies and physical rehabilitation. What if it were possible to identify those most at risk for stroke and offer "pre-treatment" to provide protection before a stroke ever occurs? Stenzel-Poore identifies stimulii that improve the brain's response through preconditioning.
 

  # # #

 

The Marquam Hill 2010-11 Lecture Series is presented by the Oregon Clinical and Translation Research Institute, the OHSU Foundation, the Marquam Hill Steering Committee and the OHSU School of Medicine. Support also is provided by Thompson Rubinstein Investment Management Inc., Springbrook Hazelnut Farm, Newberg, Ore., and Riverhouse Hotel and Convention Center, Bend, Ore.


Tamara Hargens-Bradley
Senior Director, Strategic Communications
OHSU
503-494-8231